CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (Nasdaq: CRXX) today announced the presentation of new preclinical data on its B-cell malignancy programs at the 50th Annual Meeting of the American Society of Hematology in San Francisco, California.
